You are here

Vaccines

Primary tabs

Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Members

Kathy Gilbeaux mdmcdonald MDMcDonald_me_com mike kraft

Email address for group

vaccines_global@m.resiliencesystem.org

New low cost Covid-19 vaccine developed in Texas gets approval for use in India

 

A new, low-cost Texas Children’s Hospital vaccine gets approval for use in India

A COVID-19 vaccine created at the Texas Children's Hospital Center for Vaccine Development in Houston has received emergency use authorization in India, after nearly 10 years of research and funding obstacles in 2020.

The goal is to make the vaccine – called Corbevax – available in other low- and middle-income nations across the globe to help prevent future variants of concern from forming.

“As long as we leave the southern hemisphere unvaccinated new variants of concern for us will emerge," said Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development and dean at Baylor's National School of Tropical Medicine. “The only way to stop it is to vaccinate the world and we think our [vaccine] is going to be a major contributor to that."

Problem, Solution, SitRep, or ?: 

Omicron Infections Seem to Be Milder, Three Research Teams Report, but more contageous

Three separate teams of scientists on two continents have found that Omicron infections more often result in mild illness than earlier variants of the coronavirus, offering hope that the current surge may not be quite as catastrophic as feared despite skyrocketing caseloads.

The researchers examined Omicron’s course through populations in South Africa, Scotland and England. The results in each setting, while still preliminary, all suggested that the variant was less likely to send people in hospitals.

“Given that this is everywhere and given that it’s going to be so transmissible, anything that would lower severity is going to be better,” said Natalie Dean, a biostatistician at Emory University in Atlanta.

Problem, Solution, SitRep, or ?: 

Pages

howdy folks
Page loaded in 0.934 seconds.